Introduction:
Peripheral T cell lymphoma (PTCL) continue to be, in general, associated with poor clinical outcome. In 2018, at time of disclosure of results of the T-cell Project 1 (TCP) study, we decided to launch the TCP 2.0, to have a contemporary understanding of the evolving landscape of T-cell lymphoma biology and treatment. The objective was to define the clinical features and outcomes, establishing a robust benchmark for patients with PTCL.
Materials and methods:
Data on baseline characteristics, first-line treatment, treatment response, and survival outcomes were recorded. The primary and secondary end points were 2-year PFS and OS. So far, 1,130 cases of PTCL from 118 institutions in 23 countries and classified according to the WHO 2016
Results:
The median age at diagnosis was 55.6 years (range 18–93) with 665 (58.8%) males and 465 (41.2%) females. The majority (754 pts, 71.6%) of patients had stage III/IV disease and extranodal involvement (666 pts, 60.1%). With 312 (27.6%), 172 (15.2%), 158 (14.0%), 110 (9.7%), 90 (8%), and 70 (6.2%) cases, PTCL, NOS, ALCL ALK-negative, AITL, ENKTCL, ATLL and ALCL ALK-positive subtypes, respectively.
After median follow-up of 28 months, the 2-year OS and PFS were 52 and 48%, respectively. It was 60%, 37%, 76% for patients treated with CHOEP, CHOP/CHOP-like or BV containing regimens (p<0.001). Moreover, 2-year OS was 80% for 170 patients who received ASCT as consolidation therapy.
Conclusions:
This analysis of TCP 2.0 presents a real-world data on histological subtypes, clinical presentation and treatments. Overall, the outcome of patients with PTCL is still poor. However, better understanding on the role of novel agents and ASCT is crucial to patients' management.
